Boston Scientific Corporation $BSX Shares Acquired by EPG Wealth Management LLC

EPG Wealth Management LLC lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 5.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,038 shares of the medical equipment provider’s stock after purchasing an additional 814 shares during the period. EPG Wealth Management LLC’s holdings in Boston Scientific were worth $1,830,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. DAVENPORT & Co LLC increased its position in Boston Scientific by 15.5% in the 1st quarter. DAVENPORT & Co LLC now owns 13,657 shares of the medical equipment provider’s stock valued at $1,378,000 after acquiring an additional 1,828 shares during the period. Private Trust Co. NA increased its position in Boston Scientific by 11.4% in the 1st quarter. Private Trust Co. NA now owns 2,919 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 299 shares during the period. D.A. Davidson & CO. increased its position in Boston Scientific by 4.6% in the 1st quarter. D.A. Davidson & CO. now owns 11,536 shares of the medical equipment provider’s stock valued at $1,164,000 after acquiring an additional 504 shares during the period. Finally, OneDigital Investment Advisors LLC increased its position in Boston Scientific by 14.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $1,094,000 after acquiring an additional 1,371 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BSX shares. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Canaccord Genuity Group restated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research report on Thursday, October 23rd. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Price Performance

Shares of BSX opened at $100.81 on Monday. Boston Scientific Corporation has a twelve month low of $83.38 and a twelve month high of $109.50. The stock’s 50 day moving average is $100.76 and its two-hundred day moving average is $102.40. The firm has a market capitalization of $149.37 billion, a PE ratio of 53.91, a P/E/G ratio of 2.02 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other news, Director Ellen M. Zane sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $102.24, for a total transaction of $296,598.24. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,467,460.16. The trade was a 10.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 112,891 shares of company stock worth $11,501,887 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.